UB Paderborn / Katalog / Suche / in CDI

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

The lancet oncology, 2012-05, Vol.13 (5), p.509-517

2012

Volltextzugriff (PDF)

Granulocyte Macrophage Colony-Stimulating Factor–Secreting Allogeneic Cellular Immunotherapy for Hormone-Refractory Prostate Cancer

Clinical cancer research, 2007-07, Vol.13 (13), p.3883-3891

2007

Volltextzugriff (PDF)

Granulocyte-macrophage colony-stimulating factor−transduced allogeneic cancer cellular immunotherapy: The GVAX® vaccine for prostate cancer

Urologic oncology, 2006-09, Vol.24 (5), p.419-424

2006

Volltextzugriff (PDF)

Psychiatric Comorbidity in Treatment-Seeking Anorexics and Bulimics

Journal of the American Academy of Child and Adolescent Psychiatry, 1992-09, Vol.31 (5), p.810-818

1992

Volltextzugriff (PDF)

Phase 1/2 dose‐escalation study of a GM‐CSF‐secreting, allogeneic, cellular immunotherapy for metastatic hormone‐refractory prostate cancer

Cancer, 2008-09, Vol.113 (5), p.975-984

2008

Volltextzugriff (PDF)

A clinical development paradigm for cancer vaccines and related biologics

Journal of immunotherapy, 2007-01, Vol.30 (1), p.1-15

2007

Volltextzugriff (PDF)

Patterns and Predictors of Recovery in Anorexia Nervosa and Bulimia Nervosa

Journal of the American Academy of Child and Adolescent Psychiatry, 1993-07, Vol.32 (4), p.835-842

1993

Volltextzugriff (PDF)

T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment

Cancer Immunology, Immunotherapy, 2013-02, Vol.62 (2), p.245-256

2013

Volltextzugriff (PDF)

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab

Journal for immunotherapy of cancer, 2014-09, Vol.2 (1), p.31-31, Article 31

2014

Volltextzugriff (PDF)

Lymphoid and myeloid biomarkers for clinical outcome of combined immunotherapy with granulocyte-macrophage colony-stimulating factor-tranduced allogeneic prostate cancer cells (GVAX) and ipilimumab in castration-resistant prostate cancer patients

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.2562-2562

2012

Volltextzugriff (PDF)

Abstract 5381: Activation and frequency of myeloid subsets in peripheral blood is associated with clinical outcome in prostate cancer patients treated with Prostate GVAX and anti-CTLA4

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.5381-5381

2012

Volltextzugriff (PDF)

Abstract 1229: Pre-existing NY-ESO-1-specific T cell reactivity is associated with improved clinical outcome in castration resistant prostate cancer patients treated with Prostate GVAX and ipilimumab

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.1229-1229

2013

Volltextzugriff (PDF)

Abstract 496: Inflammatory responses with infiltrating DC and functional cytotoxic T lymphocytes in the dermal vaccination sites of GVAX/ipilimumab treated prostate cancer patients

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.496-496

2013

Volltextzugriff (PDF)

Longitudinal follow-up of amenorrhea in eating disorders

Psychosomatic medicine, 1995-03, Vol.57 (2), p.121

1995

Volltextzugriff (PDF)

Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy : The GVAX® vaccine for prostate cancer : The status of cancer vaccine therapies in urology

Urologic oncology, 2006, Vol.24 (5), p.419-424

2006

Volltextzugriff (PDF)

T cell profiling reveals high CD4 super(+)CTLA-4 super(+) T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment

Cancer Immunology, Immunotherapy, 2013-02, Vol.62 (2), p.245-256

2013

Volltextzugriff (PDF)

Abstract 5512: Immune correlates of clinical response and survival in castration-resistant prostate cancer patients treated with prostate GVAX and anti-CTLA4 immunotherapy

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.5512-5512

2011

Volltextzugriff (PDF)

Abstract 2934: Increased type-2 T cell rates and coincidence of Th17 spikes with autoimmune events and PSA declines upon combined prostate GVAX and anti-CTLA4 immunotherapy

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.2934-2934

2010

Volltextzugriff (PDF)

Abstract B20: Immune vs. clinical response monitoring in patients with metastatic hormone-refractory prostate cancer receiving combined prostate GVAX and anti-CTLA4 immunotherapy

Clinical cancer research, 2010-04, Vol.16 (7_Supplement), p.B20-B20

2010

Volltextzugriff (PDF)

Increased lymphopenia results in higher percentages of FoxP3+ T cells in patients reconstituted by PBMC adoptive transfer and vaccinated (41.36)

The Journal of immunology (1950), 2009-04, Vol.182 (1_Supplement), p.41-41.36

2009

Volltextzugriff (PDF)

976: Immunotherapy with GVAX® Vaccine for Prostate Cancer Improves Predicted Survival in Metastatic Hormone Refractory Prostate Cancer: Results from Two Phase 2 Studies

The Journal of urology, 2006-04, Vol.175 (4), p.315-315

2006

Volltextzugriff (PDF)

The Impact of Parental Affective Disorder on Depression in Offspring: A Longitudinal Follow-up in a Nonreferred Sample

Journal of the American Academy of Child and Adolescent Psychiatry, 1993-07, Vol.32 (4), p.723-730

1993

Volltextzugriff (PDF)

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

Nature chemical biology, 2012-11, Vol.8 (11), p.890

2012

Volltextzugriff (PDF)

Wnt5a Directs Polarized Calcium Gradients by Recruiting Cortical Endoplasmic Reticulum to the Cell Trailing Edge

Developmental cell, 2013-09, Vol.26 (6), p.645-657

2013

Volltextzugriff (PDF)

Mitochondrial Analysis of the Most Basal Canid Reveals Deep Divergence between Eastern and Western North American Gray Foxes (Urocyon spp.) and Ancient Roots in Pleistocene California

PloS one, 2015-08, Vol.10 (8), p.e0136329-e0136329

2015

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

Granulocyte Macrophage Colony-Stimulating Factor–Secreting Allogeneic Cellular Immunotherapy for Hormone-Refractory Prostate Cancer

Granulocyte-macrophage colony-stimulating factor−transduced allogeneic cancer cellular immunotherapy: The GVAX® vaccine for prostate cancer

Psychiatric Comorbidity in Treatment-Seeking Anorexics and Bulimics

Phase 1/2 dose‐escalation study of a GM‐CSF‐secreting, allogeneic, cellular immunotherapy for metastatic hormone‐refractory prostate cancer

A clinical development paradigm for cancer vaccines and related biologics

Patterns and Predictors of Recovery in Anorexia Nervosa and Bulimia Nervosa

T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab

Lymphoid and myeloid biomarkers for clinical outcome of combined immunotherapy with granulocyte-macrophage colony-stimulating factor-tranduced allogeneic prostate cancer cells (GVAX) and ipilimumab in castration-resistant prostate cancer patients

Abstract 5381: Activation and frequency of myeloid subsets in peripheral blood is associated with clinical outcome in prostate cancer patients treated with Prostate GVAX and anti-CTLA4

Abstract 1229: Pre-existing NY-ESO-1-specific T cell reactivity is associated with improved clinical outcome in castration resistant prostate cancer patients treated with Prostate GVAX and ipilimumab

Abstract 496: Inflammatory responses with infiltrating DC and functional cytotoxic T lymphocytes in the dermal vaccination sites of GVAX/ipilimumab treated prostate cancer patients

Longitudinal follow-up of amenorrhea in eating disorders

Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy : The GVAX® vaccine for prostate cancer : The status of cancer vaccine therapies in urology

T cell profiling reveals high CD4 super(+)CTLA-4 super(+) T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment

Abstract 5512: Immune correlates of clinical response and survival in castration-resistant prostate cancer patients treated with prostate GVAX and anti-CTLA4 immunotherapy

Abstract 2934: Increased type-2 T cell rates and coincidence of Th17 spikes with autoimmune events and PSA declines upon combined prostate GVAX and anti-CTLA4 immunotherapy

Abstract B20: Immune vs. clinical response monitoring in patients with metastatic hormone-refractory prostate cancer receiving combined prostate GVAX and anti-CTLA4 immunotherapy

Increased lymphopenia results in higher percentages of FoxP3+ T cells in patients reconstituted by PBMC adoptive transfer and vaccinated (41.36)

976: Immunotherapy with GVAX® Vaccine for Prostate Cancer Improves Predicted Survival in Metastatic Hormone Refractory Prostate Cancer: Results from Two Phase 2 Studies

The Impact of Parental Affective Disorder on Depression in Offspring: A Longitudinal Follow-up in a Nonreferred Sample

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

Wnt5a Directs Polarized Calcium Gradients by Recruiting Cortical Endoplasmic Reticulum to the Cell Trailing Edge

Mitochondrial Analysis of the Most Basal Canid Reveals Deep Divergence between Eastern and Western North American Gray Foxes (Urocyon spp.) and Ancient Roots in Pleistocene California

Suchergebnisse filtern